Vivus partners its Erectile dysfunction compound with Menarini

Vivus has partnered its Erectile dysfunction compound SPEDRA (STENDRA in the U.S.) with private company Menarini for marketing in 40 European countries and Australia and New Zealand. Vivus would get up to ~$102 million in milestones plus undisclosed royalties. Menarini would pay $21m in upfront payment.

 The deal would provide meaningful cash to Vivus for funding a quicker Qsymia launch. 

Enter your email address: Delivered by FeedBurner